Amundi’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-30,721
| Closed | -$1.24M | – | 2072 |
|
|
2026
Q1 | $1.24M | Hold |
30,721
| – | – | ﹤0.01% | 1227 |
|
|
2025
Q4 | $772K | Sell |
30,721
-1,462,957
| -98% | -$34.3M | ﹤0.01% | 1330 |
|
|
2025
Q3 | $36.4M | Sell |
1,493,678
-110,427
| -7% | -$2.58M | 0.01% | 624 |
|
|
2025
Q2 | $28.6M | Buy |
1,604,105
+1,274,523
| +387% | +$23.6M | 0.01% | 649 |
|
|
2025
Q1 | $7.42M | Hold |
329,582
| – | – | ﹤0.01% | 888 |
|
|
2024
Q4 | $10.9M | Buy |
329,582
+326,604
| +10,967% | +$9.82M | ﹤0.01% | 830 |
|
|
2024
Q3 | $81.6K | Buy |
+2,978
| New | +$110K | ﹤0.01% | 1793 |
|
|
2024
Q2 | – | Sell |
-248,483
| Closed | -$11.8M | – | 1924 |
|
|
2024
Q1 | $11.8M | Buy |
248,483
+7,112
| +3% | +$453K | 0.01% | 802 |
|
|
2023
Q4 | $17.5M | Sell |
241,371
-37,593
| -13% | -$1.91M | 0.01% | 738 |
|
|
2023
Q3 | $13.5M | Buy |
278,964
+242,860
| +673% | +$10.7M | 0.01% | 777 |
|
|
2023
Q2 | $3.22M | Sell |
36,104
-769
| -2% | -$66.3K | ﹤0.01% | 1065 |
|
|
2023
Q1 | $2.85M | Buy |
36,873
+11,035
| +43% | +$637K | ﹤0.01% | 1099 |
|
|
2022
Q4 | $1.29M | Sell |
25,838
-4,570
| -15% | -$242K | ﹤0.01% | 1264 |
|
|
2022
Q3 | $1.75M | Buy |
30,408
+26,485
| +675% | +$1.57M | ﹤0.01% | 1163 |
|
|
2022
Q2 | $178K | Hold |
3,923
| – | – | ﹤0.01% | 1375 |
|
|
2022
Q1 | $221K | Hold |
3,923
| – | – | ﹤0.01% | 1377 |
|
|
2021
Q4 | $160K | Hold |
3,923
| – | – | ﹤0.01% | 1508 |
|
|
2021
Q3 | $129K | Hold |
3,923
| – | – | ﹤0.01% | 1495 |
|
|
2021
Q2 | $248K | Buy |
+3,923
| New | +$202K | ﹤0.01% | 1336 |
|
Other funds holding APLS
Amundi's APLS Position: Q2 2026 in Review
Amundi sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 30,721 shares — an estimated $1.24M sold.
Amundi first reported a position in APLS in Q2 2021 and held it in 19 quarters. The position peaked at $36.4M in Q3 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Amundi reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Amundi sold 30,721 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.24M.
- Amundi first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 19 quarters.
- Amundi's Apellis Pharmaceuticals position peaked at $36.4M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.